Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Buy" by Brokerages

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has received an average recommendation of "Buy" from the six analysts that are presently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have covered the stock in the last year is $17.33.

Several equities analysts have recently weighed in on the stock. Chardan Capital reaffirmed a "buy" rating and set a $18.00 price target on shares of Tenaya Therapeutics in a research note on Wednesday, December 18th. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Tenaya Therapeutics in a research note on Monday, February 3rd. Leerink Partners reissued an "outperform" rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Canaccord Genuity Group reissued a "buy" rating and issued a $16.00 target price on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Finally, Piper Sandler reissued an "overweight" rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th.

Institutional Investors Weigh In On Tenaya Therapeutics

Several hedge funds have recently added to or reduced their stakes in TNYA. Synovus Financial Corp acquired a new stake in Tenaya Therapeutics during the 3rd quarter valued at $28,000. SG Americas Securities LLC acquired a new stake in Tenaya Therapeutics during the 3rd quarter valued at $49,000. Spire Wealth Management acquired a new stake in Tenaya Therapeutics during the 4th quarter valued at $53,000. Commonwealth Equity Services LLC acquired a new stake in Tenaya Therapeutics during the 4th quarter valued at $64,000. Finally, Atticus Wealth Management LLC lifted its holdings in Tenaya Therapeutics by 56.3% during the 4th quarter. Atticus Wealth Management LLC now owns 47,762 shares of the company's stock valued at $68,000 after purchasing an additional 17,199 shares during the last quarter. Institutional investors and hedge funds own 90.54% of the company's stock.

Tenaya Therapeutics Price Performance

Shares of TNYA traded down $0.08 during mid-day trading on Friday, hitting $0.88. 2,201,288 shares of the company's stock were exchanged, compared to its average volume of 2,003,209. The company has a market cap of $69.71 million, a PE ratio of -0.61 and a beta of 2.84. Tenaya Therapeutics has a 52 week low of $0.86 and a 52 week high of $7.01. The company has a 50-day simple moving average of $1.78 and a 200 day simple moving average of $2.19.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.